Teriparatide Acetate is a parathyroid hormone used to treat postmenopausal women with osteoporosis and men with primary hypogonadal osteoporosis at high risk for fracture.
In male and female rats, drug increased incidence of osteosarcoma (malignant bone tumor). Because of uncertain relevance of this finding to humans, use drug only in patients for whom potential benefits outweigh potential risk. Don't administer to patient at increased baseline risk for osteosarcoma. Know that prefilled injection pen delivers 20 mcg of drug per actuation and may be reused for up to 28 days after first injection. Discard pen in protected container after 28 days, even if it's not empty. A reference to a product or service on this Site does not imply that such product or service is or will be available in your location, and does not and should not constitute an offer for sale. The products referred to on this Site may be subject to different regulatory requirements and/or other restrictions depending on the country of use.
Conditions that increase osteosarcoma risk (such as Paget's disease, unexplained alkaline phosphatase elevation, open epiphyses, skeletal radiation therapy). Inform him that he may reuse it for up to 28 days after first injection, and should then discard it in appropriate receptacle, even if it's not empty.
Administration of the exogenous human parathyroid hormone, teriparatide, distinguishes between hypoparathyroidism and pseudohypoparathyroidism by testing the patient's responsiveness to parathyroid hormone (PTH).
More about: Teriparatide Acetate
Read more>> http://www.polypeptides.net/
No comments:
Post a Comment